Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D001666:Binding Sites, Antibody / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D058950:Melanoma-Specific Antigens; D051379:Mice; D008807:Mice, Inbred BALB C; D016297:Mutagenesis, Site-Directed; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D015202:Protein Engineering / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays / Q000379:methods; D001618:beta-Lactamases / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D011355:Prodrugs; D011993:Recombinant Fusion Proteins; C108272:L49-sFv-beta-lactamase; D001618:beta-Lactamases